Back to Journals Drug Design, Development and Therapy Volume 19 A Comprehensive Review on the Pharmacokinetics and DrugDrug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist Authors Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB , Bae SK Received 17 November 2024 Accepted for publication 14 April 2025 Published 30 April 2025 Volume 2025:19 Pages 35093537 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Prof
Here we described typical and some new synthetic peptides
Perioperative dexmedetomidine improves outcomes of cardiac surgery
Do stress reactions cause abdominal obesity and comorbidities
Stop using this medicine and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting
Spotlight on Amylin Combination Strategy 22.5% Weight Loss Achieved in Phase 2 Trial "Amylin Combination Therapy to Address Nausea Side Effects Draws Attention" With Roche making a full-fledged entry into the global obesity drug market, which has been dominated by Eli Lilly and Novo Nordisk, signs are emerging of a major shift in the competitive landscape for obesity treatments
